Outcome
    Limited

    Astragalus for Immune Function

    Astragalus has extensive laboratory evidence of immune modulation and very little human outcome data. Oral supplementation at 500-1,000 mg/day is traditionally used for immune resilience, but no good randomised trial has shown fewer or shorter infections in healthy adults.

    Overview

    Astragalus has extensive laboratory evidence of immune modulation and very little human outcome data. Oral supplementation at 500-1,000 mg/day is traditionally used for immune resilience, but no good randomised trial has shown fewer or shorter infections in healthy adults.

    Verdict

    Insufficient evidence

    Strong mechanistic story, traditional pedigree, and no good human evidence that oral astragalus reduces infections in healthy adults.

    How It Works

    Astragalus polysaccharides are recognised by TLR4 on macrophages and dendritic cells, triggering maturation and cytokine release, and in culture they increase T-lymphocyte proliferation and immunoglobulin production. Astragaloside IV adds antioxidant activity and telomerase induction in lymphocytes, theorised to preserve replicative capacity in ageing immune cells. Critically, most of these effects are demonstrated in cell culture or in immunosuppressed animal models — states quite unlike a healthy adult immune system, where the same signalling may already be adequate.

    Dosing & Protocol

    Typical dose

    Recommended dose
    No established oral dose; oral trials used roughly 1-6 g/day of root or extract
    Expected timeframe
    8-12 weeks

    Protocol

    never
    Do not add astragalus to cancer treatment without your oncology team knowing
    studied dose
    Intravenous astragalus preparations alongside platinum chemotherapy in Chinese oncology trials; oral trials used roughly 1-6 g/day of dried root or equivalent extract
    evidence note
    Verdict is insufficient - the strongest data uses intravenous preparations that do not translate to capsules
    what happened
    Meta-analyses of the intravenous oncology supportive-care trials are the strongest signal, but they are largely small Chinese trials at high risk of bias and say nothing about capsules in healthy people. Oral astragalus has no good evidence for preventing or shortening common infections
    if you still trial it
    1-6 g/day of dried root or an equivalent standardised extract with food, judged on a count of infection days over a season

    Evidence

    What the studies say

    The human evidence divides into three uneven parts. The strongest is oncology supportive care: meta-analyses of Chinese trials adding intravenous astragalus preparations to platinum-based chemotherapy report reduced nausea and improved performance status, but the trials are small, often unblinded, and use a parenteral route no oral supplement replicates. The second is diabetic nephropathy, where randomised trials report reduced proteinuria over three to six months with reasonable consistency. The third — general immune support in healthy adults, which is how the supplement is actually marketed — has essentially no adequately powered randomised evidence. Given astragaloside IV oral bioavailability below 3%, the gap between the injectable trial data and an oral capsule is pharmacological, not merely methodological.

    Standardized astragalus extract for attenuation of the immunosuppression induced by strenuous physical exercise: randomized controlled trial

    Score: 5/10
    2021
    rct
    n=18

    Latour E, Arlet J, Latour EE +2 more

    AMR restored the immunological balance in strenuously trained athlets through a stabilization of NK and Treg cells.

    View source

    Safety

    Caveats

    The immunostimulant profile makes this genuinely inappropriate in autoimmune disease and after transplant. Oral bioavailability of the main saponin is poor, so it is unclear that oral products reproduce effects seen with injectable preparations in trials.

    Less likely to help if

    Healthy adults with no underlying immune deficit are the group least likely to show any measurable change, and are also the main market.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.